

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Tong Ren Tang Technologies Co. Ltd.
北京同仁堂科技發展股份有限公司

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1666)

VOLUNTARY ANNOUNCEMENT
RECEIVING THE CERTIFICATE OF REGISTRATION OF PROPRIETARY
CHINESE MEDICINE

This announcement is made by Tong Ren Tang Technologies Co. Ltd. (the “**Company**”, and together with its subsidiaries, the “**Group**”) on a voluntary basis for the purpose of keeping the shareholders and potential investors of the Company informed of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that Beijing Tong Ren Tang Chinese Medicine Company Limited (“**Tong Ren Tang Chinese Medicine**”), a subsidiary of the Company, whose shares are listed on The Stock Exchange of Hong Kong Limited (stock code: 3613), recently received the Certificate of Registration of Proprietary Chinese Medicine (《中成藥註冊證明書》) issued by the Chinese Medicine Council of Hong Kong, allowing “Danggui Buxue Keli 【Tong Ren Tang】”(當歸補血顆粒【同仁堂】) to be sold in Hong Kong. The relevant details are as follows:

I. Basic Information of the Medicine

Name of the medicine: Danggui Buxue Keli 【Tong Ren Tang】
(當歸補血顆粒【同仁堂】)

Registrant and address: Beijing Tong Ren Tang Chinese Medicine Company Limited
at 3 Dai King Street, Tai Po Industrial Estate, New Territories, Hong Kong

Registration number: HKC-18604

Certificate validity period: Until 25 April 2029

II. Other Related Information of the Medicine

The function and main indications of the “Danggui Buxue Keli 【Tong Ren Tang】 ” are to tonify qi and engender blood. It is used to treat fever caused by patterns of blood deficiency and floating yang. The symptoms include fever with a red complexion, vexation and thirst with a desire to drink. The pulses are surging, large, and deficient; however, forceless pulses appear whilst under heavy pressure. As of the date of this announcement, Tong Ren Tang Chinese Medicine has cumulatively invested approximately HK\$800 thousand (unaudited) in the research and development of “Danggui Buxue Keli 【Tong Ren Tang】 ”. This product has not yet been launched for sales in market.

III. Impact on the Group and Risk Warning

Upon obtaining the Certificate of Registration of Proprietary Chinese Medicine issued by the Chinese Medicine Council of Hong Kong, “Danggui Buxu Keli 【Tong Ren Tang】 ” produced by Tong Ren Tang Chinese Medicine can be sold in Hong Kong, which is conducive to expanding the product lines of the Group and beneficial to the market expansion of the Group. The obtaining of the aforementioned certificate of registration will not have any material impact on the production, operation and performance of the Group for the time being. The sales of pharmaceutical products can be influenced by factors such as change in the policy environment, exchange rate fluctuations and market competition in the Hong Kong region.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Tong Ren Tang Technologies Co. Ltd.
Di Shu Bing
Chairman of the Board

Beijing, the PRC
30 April 2024

As at the date of this announcement, the Board comprises Mr. Di Shu Bing, Mr. Chen Jia Fu and Ms. Feng Zhi Mei as executive Directors, Mr. Jin Tao, Ms. Wang Chun Rui and Ms. Feng Li as non-executive Directors, Mr. Ting Leung Huel, Stephen, Ms. Chan Ching Har, Eliza and Mr. Zhan Yuan Jing as independent non-executive Directors.